Reza Vaghefi Hosseini, MD
Infectious Disease · Las Vegas, NVNPI 1184868093
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,186 of the $1,332 with a category attached, or 89.0%. It is spread thinly across 10 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $584 and has fallen 91.6% since, to $49 in 2024. That places this record below the midpoint for infectious disease clinicians in NV, where the typical reported total is $1,077.
Across 55 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$265
- Paratek Pharmaceuticals, Inc.$260
- Astellas Pharma US Inc$214
- Merck$172
- Gilead$171
- Tetraphase Pharmaceuticals, Inc.$115
- plus $135 from 4 others
What the payments were for
- Food & beverage$1,18689%
- Education$14611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 12 | $265 |
| Paratek Pharmaceuticals, Inc. | 8 | $260 |
| Astellas Pharma US Inc | 6 | $214 |
| Merck | 9 | $172 |
| Gilead | 8 | $171 |
| Tetraphase Pharmaceuticals, Inc. | 6 | $115 |
| Viiv Healthcare Company | 2 | $49 |
| Johnson & Johnson | 2 | $36 |
| La Jolla Pharmaceutical Company | 1 | $26 |
| Quidel Corporation | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$111
How this compares
$1,332 in reported general payments places this provider in the 50th percentile of 65 infectious disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 64 | $119,211 |
| ErtapenemErtapenem Sodium | 64 | $31,271 |
| Meropenem | 17 | $4,813 |
| Cefepime Hcl | 20 | $3,419 |
| CeftriaxoneCeftriaxone Sodium | 41 | $2,133 |
| Cefazolin Sodium | 31 | $1,416 |
| Ethambutol Hcl | 21 | $661 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $180 |
| Doxycycline Hyclate | 16 | $166 |
| Azithromycin | 19 | $61 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Las Vegas
- Alireza FarabiLas Vegas$588K
- Dhiresh JoshiLas Vegas$96K
- Shaker ItaniLas Vegas$52K
- Dhaval ShahLas Vegas$27K
- Alka RebentishLas Vegas$23K
- Ronald ShockleyLas Vegas$13K
- Chukwudum UcheLas Vegas$13K
- John OreillyLas Vegas$8K
- Li-Chien ChenLas Vegas$8K
- Naima ZaheerLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.